Kimberly-Clark Elects Joseph Romanelli to its Board of Directors

Rhea-AI Summary

Kimberly-Clark (NYSE: KMB) announced the election of Joseph Romanelli to its board of directors, expanding the board from 12 to 13 members. Romanelli currently serves as president of Human Health International for Merck & Co. (MSD), where he oversees 75-plus markets outside the U.S. and leads a team of 14,000 colleagues. Prior to his current role at MSD, which began in 2022, he was CEO of JiXing Pharmaceuticals and held various strategic and operational positions at MSD and Schering-Plough over 25 years.

Positive

• Board expansion adds expertise in global healthcare and international markets
• New director brings extensive leadership experience from major pharmaceutical companies
• Strategic addition aligns with company's Powering Care strategy

Negative

• None.

DALLAS, Nov. 13, 2024 /PRNewswire/ -- Kimberly-Clark Corporation (NYSE: KMB) today announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, USA, ("MSD") has been elected to its board of directors, effective immediately. In connection with the election, Kimberly-Clark's board size will increase from 12 to 13 directors.

"Joe Romanelli is an outstanding addition to the Kimberly-Clark Board of Directors," said Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our Powering Care strategy, we will benefit from Joe's global leadership experience and his expertise in using leading-edge science to save and improve lives around the world."

Mr. Romanelli has served as president of Human Health International for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the U.S. and leads a team of 14,000 colleagues. Prior to joining MSD, Mr. Romanelli served as the chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company. Previously, he served in a variety of strategic and operational roles with increasing responsibility at MSD and Schering-Plough for 25 years.

About Kimberly-Clark
Kimberly-Clark (NYSE: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries. Fueled by ingenuity, creativity, and an understanding of people's most essential needs, we create products that help individuals experience more of what's important to them. Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 70 countries. We use sustainable practices that support a healthy planet, build strong communities, and ensure our business thrives for decades to come. We are proud to be recognized as one of the World's Most Ethical Companies(R) by Ethisphere for the fifth year in a row and one of Fortune's Most Innovative Companies in America in 2024. To keep up with the latest news and to learn more about the company's 150-year history of innovation, visit the Kimberly-Clark website.

[KMB-F]

View original content:https://www.prnewswire.com/news-releases/kimberly-clark-elects-joseph-romanelli-to-its-board-of-directors-302303461.html

SOURCE Kimberly-Clark Corporation

FAQ

When did Joseph Romanelli join Kimberly-Clark's (KMB) board of directors?

Joseph Romanelli joined Kimberly-Clark's board of directors in November 2023, immediately upon his election.

How many directors are now on Kimberly-Clark's (KMB) board after Romanelli's election?

Following Joseph Romanelli's election, Kimberly-Clark's board increased from 12 to 13 directors.

What is Joseph Romanelli's current position outside of Kimberly-Clark (KMB)?

Joseph Romanelli currently serves as president of Human Health International for Merck & Co. (MSD), overseeing 75-plus markets outside the U.S. and leading 14,000 colleagues.